ANIX — Anixa Biosciences Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 715446 ·
Last close
$2.67
Market Cap
$92.82M
52W High
$5.46
52W Low
$2.32
ADV30
195,628
Next earnings
2027-01-12

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jul 2026 0 — -2,737,000 -2,606,000 15,074,000 1,398,000 1,873,000
Apr 2026 0 — -2,647,000 -2,516,000 14,865,000 1,477,000 1,641,000
Jan 2026 0 — -2,716,000 -2,565,000 15,233,000 1,547,000 1,387,000
Oct 2025 0 — -2,876,000 -2,695,000 16,080,000 1,244,000 2,130,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,376,000
Investing CF
$2,059,000
Financing CF
$5,220,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.30
As of
2026-09-13

Balance + Analyst (yfinance extras)

Retained Earnings
$-259,364,000
Inventory
—
Receivables
$56,000
ST Investments
$12,466,000
EBIT TTM
$-10,976,000
Pretax Income TTM
$-10,468,000
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Oct 2025 0 -11,701,000 -10,927,000 16,080,000 2,130,000 15,161,000 -7,173,000
Oct 2024 0 -13,831,000 -12,554,000 21,591,000 2,703,000 19,998,000 -7,335,000
Oct 2023 210,000 -11,011,000 -9,811,000 25,522,000 2,151,000 24,337,000 -6,209,000
Oct 2022 0 -13,875,000 -13,595,000 30,412,000 2,212,000 29,047,000 -6,492,000

TTM Snapshot

Revenues TTM
$14,394,000
NetIncome TTM
$-10,382,000
OpCashFlow TTM
—
Assets (Latest)
$15,074,000
Forward EPS
$-0.31

Max Pain — expiry 2027-01-15

max pain strike: $2.50 · spot: $2.71 · call oi: 1,240 · put oi: 102
Expected Move to 2027-01-15: ±$0.75 (27.68%) — implied range $1.96 – $3.46 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PMVP PMV Pharmaceuticals, Inc. $92.15M $1.22 —
RTSN Retension Pharmaceuticals, Inc. $95.06M $11.41 —
NBP NovaBridge Biosciences $95.10M $0.82 —
GNLX GENELUX Corp $90.49M $2.00 —
NKTX Nkarta, Inc. $89.53M $1.25 —

News headlines (Yahoo Finance, 1h cache)

Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial
2026-11-18 13:25 · Yahoo
Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
2026-11-04 13:35 · Yahoo
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
2026-10-26 12:30 · Yahoo
Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
2026-10-13 13:00 · Yahoo
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
2026-10-13 12:40 · Yahoo
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
2026-10-05 12:15 · Yahoo
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
2026-10-01 12:35 · Yahoo
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
2026-09-21 12:45 · Yahoo
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
2026-09-16 13:15 · Yahoo
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-09-11 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.